Genetic Variation of Inflammatory Genes to Ischemic Stroke Risk in a Chinese Han Population

Zhongqiu Zhang^{1,2,*}Yanping Mei^{3,*}Mengqiu Xiong³Fang Lu^{1,2}Xianghong Zhao^{1,2}Junrong Zhu^{1,2}Bangshun He^{1,3}

¹School of Basic Medicine & Clinical Pharmacy, China Pharmaceutical University, Nanjing, 211198, Jiangsu Province, People's Republic of China;

²Department of Pharmacy, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, Jiangsu Province, People's Republic of China; ³Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, Jiangsu Province, People's Republic of China

*These authors contributed equally to this work

Background: Inflammation proteins play an important role in stroke occurrence. *IL1A*, *IL1B*, *PTGS2*, *MMP2*, and *MMP9* were the mediators involved in the immune response, and the association of these genetic variations with ischemic stroke (IS) risk was still unclear.

Methods: To investigate the susceptibility of genetic variations of *IL1A*, *IL1B*, *PTGS2*, *MMP2*, and *MMP9* to IS risk, we performed a case-control study involving 299 patients and 300 controls in a Chinese population. Thirteen genetic variations of investigated genes of all participants were genotyped using an improved multiplex ligase detection-reaction technique.

Results: No SNP in all genes showed an association with overall IS. However, in subgroup analysis, *PTGS2* rs689466 (dominant model: CT vs TT – OR_{adjusted} = 2.51, 95% CI: 1.22–5.16, *p* = 0.012; co-dominant model: CT/CC vs TT – OR_{adjusted} = 2.53, 95% CI: 1.26–5.07, *p* = 0.009; additive model – OR_{adjusted} = 2.26, 95% CI: 1.19–4.28, *p* = 0.013) and rs5275 (dominant model: GG vs AA – OR_{adjusted} = 0.31, 95% CI: 0.12–0.80, *p* = 0.016; co-dominant model: GA/GG vs AA – OR_{adjusted} = 0.45, 95% CI: 0.21–0.95, *p* = 0.036; additive model – OR_{adjusted} = 0.60, 95% CI: 0.39–0.92, *p* = 0.020) were associated with IS type of small-vessel occlusion.

Conclusion: Our study suggested that *PTGS2* rs689466 C and rs5275 A were potentially associated with IS subtype of small-vessel occlusion. Our result should be confirmed with further large sample sized studies.

Keywords: ischemic stroke, genetic variation, *IL1A*, *IL1B*, *PTGS2*, *MMP2*, *MMP9*, risk

Introduction

Stroke is a neurological disease caused by vascular, leading to considerably high disability and mortality. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) showed that stroke and ischemic heart were the top cause of disability over the age of 50.¹ Depending on regional epidemiology, stroke is classified as ischemic stroke (IS) and hemorrhagic stroke, and the most common of which is IS, accounting for 87% of all stroke patients.

In the clinical setting, according to the etiology of ischemic, five subtypes were divided for IS, which was developed for the TOAST study:² 1) large-artery atherosclerosis, 2) small-vessel occlusion, 3) cardioembolism, 4) other determined etiology, and 5) undermined etiology. The most common cause of ischemic is due to arterial occlusion, and the rarer cause is cerebral veins or venous sinuses.³ There are many causes of stroke, such as hypertension, diabetes, dyslipidemia, smoking, and genetic background. Especially, genetic background accounts for 30–40% of IS.⁴

Correspondence: Bangshun He
Department of Laboratory Medicine,
Nanjing First Hospital, Nanjing Medical
University, Nanjing, Jiangsu Province,
210006, People's Republic of China
Email bhe@njmu.edu.cn

Junrong Zhu
Department of Pharmacy, Nanjing First
Hospital, Nanjing Medical University, 68
Changle Road, Nanjing, Jiangsu Province,
210006, People's Republic of China
Email junrong_zhu@aliyun.com

Inflammation contributes across the spectrum of IS.⁵ Firstly, inflammation might not only promote thrombus formation but also inhibit endogenous fibrinolysis to enhance clot stability.⁶ Secondly, the inflammatory mediators promote immune cells and solutes into the brain parenchyma and damage the blood–brain barrier further, and contribute the thrombogenesis.^{7,8} Moreover, some inflammatory mediators might be the predictor factors of IS clinical outcome.^{9,10} Multiple inflammation-associated mediators are involved in the process.¹¹ For example, the interleukin (IL)-1 family, as a highly active proinflammatory cytokine, is a main regulator of inflammation and triggers inflammatory cascade response by binding to the IL1 receptor.¹² *IL1A* and *IL1B* are distinct members of *IL1* genes and encode IL1 α and IL1 β , respectively. Experimental studies show that abnormal IL1 α and IL1 β levels will lead to inflammatory diseases¹² and involve a variety of cellular activities, including adhesion molecule induction and procoagulant activity, which present a higher inflammatory reaction and affect the development of atherosclerosis resulting in IS.¹³ Studies showed IL1 β had significantly higher blood levels for stroke¹⁴ and contribute to the occurrence of stroke.¹⁵ Prostaglandin-endoperoxide synthase (PTGS2), known as COX2, is an important induced enzyme in vascular endothelial cells, smooth muscle cells, and platelets. It is induced by cytokines and growth factors¹⁶ and is closely associated with the formation of atherosclerosis.¹⁷ Multiple studies reported an association between *PTGS2* genetic polymorphisms and IS risk.^{18,19} Matrix metalloproteinases (MMPs), as a category of proteolytic zinc-dependent enzymes, play an important role in the degradation of the extracellular matrix and take part in the progression of atherosclerosis by triggering the migration and proliferation of smooth muscle cells and by causing destabilization of atherosclerotic plaques.²⁰ Previously, studies have reported that the MMPs protein levels elevate result in blood–brain barrier dysfunction and impact the extent of the infarct,^{21–23} and the polymorphisms of *MMPs* have been evaluated in IS.^{24,25} The association with IS of *MMPs* is focused on *MMP2* and *MMP9*²⁶, and the high expression level of *MMP2* and *MMP9* has been reported that was associated with increased risk of IS and major disability.^{15,27–29}

Given the putative role of the above gene involved in the occurrence of IS, to identify the risk of the genetic background to IS risk, we conducted a case–control association study to assess the association between 13 single nucleotide polymorphisms (SNPs) in *IL1B*, *IL1A*, *PTGS2*, *MMP9*, *MMP2*, and risk of IS.

Materials and Methods

Study Subjects

A total of 299 patients diagnosed based on clinical symptoms, physical examination, and head computed tomography or magnetic resonance imaging, and 300 healthy controls were enrolled in this case–control study.³⁰ All patients presented with signs and symptoms lasting more than 24 hours which sudden onset of focal or global neurological deficits. Patients with a history of transient ischemic attacks, hemorrhagic stroke, cerebral trauma, cardiogenic thrombosis, coagulation disorders, autoimmune disease, tumors, or peripheral vascular disease were excluded. The etiology of IS was classified according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) as large-artery atherosclerosis, cardioembolism, small-vessel atherosclerosis, and stroke of other etiology.

Healthy control subjects were recruited during the same period from the Health Medical Center of Nanjing First Hospital. The healthy controls were confirmed according to the routine health examination results. For the controls, the hematologic diseases, tumors, autoimmune diseases, liver ailments, and genetic diseases were excluded. All enrolled participants come from the same geographic region: Nanjing City, Jiangsu, China. The patient information was collected from the hospital information system, and the health control information was from questionnaires. Declaration of Helsinki and all procedures were approved by the Institutional Review Board of Nanjing First Hospital, and all participants were written informed consent.

DNA Extraction and Genotyping

The SNPs of *IL1A*, *IL1B*, *PTGS2*, *MMP2*, and *MMP9* were selected and retrieved from the National Center for Biotechnology Information dbSNP database (<https://www.ncbi.nlm.nih.gov/snp/>), and then selected potential genes based on the following criteria: 1) positioned in exons, promoter regions, 5'UTRs, 3'UTRs, or splice sites; 2) minor-allele frequency $\geq 5\%$; and 3) had been reported to be associated with IS risk. Finally, thirteen genetic variations were selected (see [Table S1](#) for details). The DNA extraction and genotyping were performed as previously described.³⁰ Genotyping used a method based on an improved multiplex ligase detection reaction technique developed by Genesky Biotech (Shanghai, China). In detail, firstly, genetic-variation loci were amplified by multiplex polymerase chain reaction, and then the amplification products were purified with nuclease and shrimp

alkaline enzyme. Finally, each locus contained two 5'terminal allele-specific probes and a 3'terminal-specific probe of fluorescent tags, and ligation products were analyzed with an ABI 3730XL finally.

Statistical Analysis

For the distribution of genotypes, a goodness-of-fit Chi-square test was adopted to test the Hardy–Weinberg equilibrium (HWE) in the control group. Differences in the demographic characteristics of the two groups were assessed by *t*-test or χ^2 test. Logistic regression was applied to calculate the susceptibility of polymorphisms to IS risk with ORs and 95% CIs based on different genetic models: Dominant model (Rare allele homozygote (RR) or heterozygous (WR) vs wild-type homozygote (WW) genotypes), co-dominant model (RR+WR vs WW), and additive model (WW vs WR vs RR).³¹ *P* < 0.05 was considered statistically significant.

Results

Characteristics of the Study Population

A total of 299 patients with IS and 300 healthy controls were enrolled in this study. Their demographic data and clinical characteristics are summarized in [Table S2](#). There were no significant statistical differences in sex (*p*=0.312), drinking (*p*=1.000), or chol (*p*=0.623), but there were significant differences between the two groups with age (*p*<0.001), smoking (*p*<0.001), hypertension (*p*<0.001). For clinical characteristics, levels of TG (*p*<0.001), GLU (*p*<0.001), HYG (*p*<0.001), and CRP (*p*<0.001) were significantly higher in patients than in controls. In contrast, levels of HDL in patients were significantly lower than in controls (*p*=0.004). A total of 56 patients were identified as having small-vessel occlusion, 116 having large-artery, 28 having cardioembolism, and 99 having other etiologies. The HWE result showed that all genotypes were not derived from controls ([Table S1](#)).

Association Between and Risk of Stroke

Logistic regression analysis revealed that no SNP showed any association with the risk of IS in all genes ([Table 1](#)) and subgroup stratified by sex ([Table 2](#)). However, subgroup analysis by subtypes of IS showed that *PTGS2* rs689466 (dominant model: CT vs TT – OR_{adjusted}=2.51, 95% CI: 1.22–5.16, *p*=0.012; co-dominant model: CT/CC vs TT – OR_{adjusted}=2.53, 95% CI: 1.26–5.07, *p*=0.009;

additive model – OR_{adjusted}=2.26, 95% CI: 1.19–4.28, *p*=0.013) was associated with increased risk of IS type of small-vessel occlusion. However, the *PTGS2* rs5275 (dominant model: GG vs AA – OR_{adjusted}=0.31, 95% CI: 0.12–0.80, *p*=0.016; co-dominant model: GA/GG vs AA – OR_{adjusted}=0.45, 95% CI: 0.21–0.95, *p*=0.036; additive model – OR_{adjusted}=0.60, 95% CI: 0.39–0.92, *p*=0.020) were associated with decreased risk of IS type of small-vessel occlusion. Additionally, the SNP *MMP9* rs3918242 was observed to be susceptible to the cardioembolic subtype of IS with dominant model (CT vs CC – OR_{adjusted}=0.31, 95% CI: 0.11–0.91, *p*=0.033) but not other genetic models ([Table 3](#)). No other genotypes were observed significant differences in stroke risk.

Discussion

The population-based case–control association study had not observed associated SNPs with overall IS. However, *PTGS2* rs689466 (C allele) and rs5275 (A allele) were associated with IS subtype of small-vessel occlusion.

Inflammatory proteins play an important role in the pathogenesis of stroke. Inflammatory genes, such as C-reactive protein (*CRP*), interleukin (*IL*) 6, transforming growth factor β 1 (*TGFBI*), were identified to contribute to stroke risk.^{11,32–34} It is well known that the elevated levels of inflammatory markers may reflect a high burden of atherosclerosis and thrombosis, which contribute to the occurrence of IS.^{13,35}

PTGS2, with loci on chromosome 1, is an inducible enzyme that catalyzes arachidonic acid into prostaglandins and plays a vital role in inflammation.³⁶ The expression of *PTGS2* is increased significantly in stroke with inflammatory cells infiltrating, and relevant studies have reported that it is associated with IS.¹⁸ The rs689466 (*PTGS2* –1195T>C) is located in the *PTGS2* promoter, and the –1195T allele displays a higher *PTGS2* level than the –1195C allele.³⁷ The rs5275 (8473A>G) is located in *PTGS2* 3'-UTR, and the 8273A allele could regulate *PTGS2* higher expression by maintaining the stability of *PTGS2* mRNA,^{38,39} indicating rs5275A allele, associated with increased *PTGS2* expression, induce the risk of IS. According to our study, rs689466 (C allele) and rs5275 (A allele) were associated with small-vessel occlusion whether dominant model or additive model, but have no significant difference in all IS. The reason may be that *PTGS2* induces thrombosis¹⁷ which causes thrombotic occlusion of small vessels.³⁷ Chen reported that rs689466 was associated with all IS and the effects were confined to small-vessel occlusion but not large-artery.³⁷

Table I Genotype Distribution of the Polymorphisms in All Participants

Genotype	Patients, n(%)	Controls, n(%)	OR(95% CI) ^a	P value
IL1B				
rs16944				
AA	77(25.75)	89(29.67)	Reference	
GA	155(51.84)	147(49.00)	1.10(0.74–1.65)	0.641
GG	67(22.41)	64(21.33)	1.11(0.68–1.82)	0.672
GA/GG	222(74.25)	211(70.33)	1.12(0.76–1.63)	0.571
rs1143627				
GG	77(25.75)	88(29.33)	Reference	
GA	151(50.50)	145(48.33)	1.06(0.71–1.59)	0.779
AA	71(23.75)	67(22.33)	1.13(0.69–1.83)	0.632
GA/AA	222(74.25)	212(70.67)	1.09(0.75–1.60)	0.647
rs1143634				
GG	285(95.32)	288(96.00)	Reference	
GA	12(4.01)	12(4.00)	0.87(0.37–2.05)	0.750
AA	2(0.67)	0(0.00)	–	0.988
GA/AA	14(4.68)	12(4.00)	0.96(0.42–2.19)	0.917
IL1A				
rs1800587				
GG	239(79.93)	252(84.00)	Reference	
GA	56(18.73)	45(15.00)	1.33(0.85–2.09)	0.213
AA	4(1.34)	3(1.00)	1.02(0.21–4.99)	0.977
GA/AA	60(20.07)	48(16.00)	1.31(0.84–2.03)	0.230
PTGS2				
rs20417				
CC	265(88.63)	266(88.67)	Reference	
GC	34(11.37)	34(11.33)	1.03(0.60–1.76)	0.917
GG	0(0)	0(0)	–	–
GC/GG	34(11.37)	34(11.33)	1.03(0.60–1.76)	0.917
rs689466				
TT	197(65.89)	180(60.00)	Reference	
CT	95(31.77)	109(36.33)	0.80(0.56–1.15)	0.222
CC	7(2.34)	11(3.67)	0.52(0.19–1.42)	0.201
CT/CC	102(34.11)	120(40.00)	0.77(0.54–1.10)	0.149
rs5275				
AA	90(30.10)	98(32.67)	Reference	
GA	139(46.49)	149(49.67)	0.98(0.67–1.45)	0.937
GG	70(23.41)	53(17.67)	1.54(0.93–2.55)	0.094
GA/GG	209(69.9)	202(67.33)	1.10(0.77–1.59)	0.597
MMP9				
rs17576				
GG	150(50.17)	155(51.67)	Reference	
GA	118(39.46)	114(38.00)	1.04(0.72–1.49)	0.843
AA	31(10.37)	31(10.33)	1.03(0.59–1.82)	0.908
GA/AA	149(49.83)	145(48.33)	1.03(0.74–1.45)	0.849

(Continued)

Table I (Continued).

Genotype	Patients, n(%)	Controls, n(%)	OR(95% CI) ^a	P value
rs3918242				
CC	245(81.94)	254(84.67)	Reference	
CT	51(17.06)	42(14.00)	1.37(0.86–2.18)	0.193
TT	3(1.00)	4(1.33)	0.86(0.17–4.36)	0.852
CT/TT	54(18.06)	46(15.33)	1.32(0.84–2.08)	0.230
rs9509				
TT	189(63.21)	184(61.33)	Reference	
CT	100(33.44)	101(33.67)	0.94(0.66–1.35)	0.750
CC	10(3.34)	15(5.00)	0.65(0.27–1.54)	0.325
CT/CC	110(36.79)	116(38.67)	0.91(0.64–1.28)	0.575
MMP2				
rs7201				
AA	173(57.86)	178(59.33)	Reference	
CA	105(35.12)	103(34.33)	0.90(0.62–1.29)	0.556
CC	21(7.02)	19(6.33)	1.13(0.56–2.29)	0.741
CA/CC	126(42.14)	122(40.67)	0.93(0.66–1.32)	0.694
rs2285053				
CC	171(57.19)	176(58.67)	Reference	
CT	102(34.11)	103(34.33)	1.03(0.71–1.48)	0.895
TT	26(8.70)	21(7.00)	1.39(0.73–2.64)	0.311
CT/TT	128(42.81)	124(41.33)	1.08(0.77–1.53)	0.643
rs243864				
TT	238(79.60)	238(79.33)	Reference	
CT	56(18.73)	58(19.33)	0.89(0.57–1.37)	0.583
CC	5(1.67)	4(1.33)	2.45(0.60–9.91)	0.210
CT/CC	61(20.40)	62(20.67)	0.95(0.63–1.45)	0.821

Note: ^aAdjusted for age, sex, smoking, and drinking.

Shan also showed that rs689466 was associated with small vessel disease,⁴⁰ which was consistent with our results. However, Zhao reported that rs68944 has a higher risk in LAA was dissimilar to our study,⁴¹ but its gene–gene interactions of three *PTGS* genes including rs689466 were an association with small vessel occlusion. For rs5275, another *PTGS2* associate gene, few studies have discussed the association between rs5275 and stroke risk to date, but it was reported that was impacted the IS outcome.⁴² Our study showed that rs5275 was associated with small-vessel occlusion as well as rs689466, so more large sample studies need to be conducted.

MMP9 locates on chromosome 20q12–q13, is a member of the MMP family, and plays a role in the progression of IS.⁴³ The *MMP9* rs3918242, within the promoter region (–1562 C>T), T allele led to a higher promoter activity of the *MMP9*.^{44–46} The conclusions of rs3918242 T allele for

stroke risk were controversial.^{47–49} A meta-analysis including 14 control studies with 3233 IS patients and 3123 controls showed that *MMP9* rs3918242 variants contributed to increasing the risk of IS,⁴⁹ and the report showed that T allele carriers of rs3918242 polymorphism probably contributed to increasing in IS than C allele. However, our study shows that CT decreases the risk of cardioembolic stroke than CC. The reason for the contradiction with previous studies may be due to smaller patients included in this study in that only 7 patients with CT genes and no TT genes among the patients with cardioembolic stroke in this study, which may affect the statistical power. Moreover, there was no significant difference under the additive model. For the difference above, our result should be verified by further large sample sized study.

A total of thirteen SNPs were also included in this study. Although these SNPs have been reported to affect the expression of some inflammatory proteins that contribute to the risk

Table 2 Genotype Distribution of Polymorphisms in All Participants Stratified by Sex

Genotype	Male		Female	
	OR(95% CI) ^a	P-value ^a	OR(95% CI) ^a	P-value ^a
IL1B				
rs16944				
AA	Reference		Reference	
GA	1.35(0.80,2.29)	0.264	0.75(0.37,1.52)	0.424
GG	1.37(0.72,2.61)	0.335	0.88(0.38,2.07)	0.759
GA/GG	1.36(0.83,2.23)	0.223	0.81(0.42,1.55)	0.517
Additive model	1.18(0.86,1.61)	0.302	0.90(0.59,1.39)	0.636
rs1143627				
GG	Reference		Reference	
GA	1.26(0.74,2.14)	0.402	0.76(0.38,1.55)	0.454
AA	1.44(0.77,2.70)	0.259	0.83(0.36,1.94)	0.671
GA/AA	1.32(0.80,2.17)	0.276	0.81(0.42,1.55)	0.517
Additive model	1.20(0.88,1.63)	0.249	0.89(0.60,1.36)	0.581
rs1143634				
GG	Reference		Reference	
GA	0.60(0.19,1.86)	0.371	1.43(0.33,6.27)	0.634
AA	—	—	—	—
GA/AA	0.70(0.24,2.03)	0.506	1.43(0.33,6.27)	0.634
Additive model	0.82(0.32,2.10)	0.687	1.43(0.33,6.27)	0.634
IL1A				
rs1800587				
GG	Reference		Reference	
GA	1.20(0.68,2.14)	0.531	1.50(0.68,3.33)	0.317
AA	1.40(0.08,24.45)	0.819	0.60(0.08,4.49)	0.622
GA/AA	1.21(0.68,2.13)	0.515	1.35(0.64,2.88)	0.432
Additive model	1.20(0.70,2.06)	0.512	1.18(0.62,2.27)	0.615
PTGS2				
rs20417				
CC	Reference		Reference	
GC	0.89(0.41,1.92)	0.769	1.11(0.48,2.52)	0.804
GG	—	—	—	—
GC/GG	0.89(0.41,1.92)	0.769	1.11(0.49,2.52)	0.804
Additive model	0.89(0.41,1.92)	0.769	1.10(0.49,2.52)	0.804
rs689466				
TT	Reference		Reference	
CT	0.73(0.45,1.18)	0.197	0.81(0.44,1.47)	0.483
CC	0.47(0.11,2.08)	0.325	0.46(0.11,1.95)	0.293
CT/CC	0.71(0.44,1.13)	0.151	0.76(0.42,1.36)	0.357
Additive model	0.72(0.48,1.10)	0.130	0.75(0.46,1.24)	0.266
rs5275				
AA	Reference		Reference	
GA	0.77(0.46,1.28)	0.310	1.24(0.64,2.41)	0.517
GG	1.77(0.93,3.39)	0.085	1.16(0.48,2.79)	0.744
GA/GG	0.97(0.61,1.55)	0.899	1.21(0.65,2.27)	0.552
Additive model	1.20(0.88,1.64)	0.254	1.08(0.71,1.64)	0.713

(Continued)

Table 2 (Continued).

Genotype	Male		Female	
	OR(95% CI) ^a	P-value ^a	OR(95% CI) ^a	P-value ^a
MMP9				
rs17576				
GG	Reference		Reference	
GA	0.93(0.58,1.49)	0.768	1.23(0.66,2.30)	0.518
AA	1.01(0.48,2.12)	0.987	1.17(0.47,2.90)	0.742
GA/AA	0.95(0.61,1.47)	0.801	1.12(0.68,2.16)	0.513
Additive model	0.97(0.70–1.36)	0.889	1.12(0.74–1.70)	0.592
rs3918242				
CC	Reference		Reference	
CT	1.13(0.62,2.04)	0.689	1.96(0.82,4.69)	0.132
TT	2.52(0.35,18.32)	0.363	–	–
CT/TT	1.19(0.67,2.12)	0.552	1.53(0.67,3.48)	0.315
Additive model	1.23(0.73–2.06)	0.442	1.18(0.56–2.48)	0.665
rs9509				
TT	Reference		Reference	
CT	0.96(0.60,1.54)	0.867	0.76(0.41,1.41)	0.389
CC	0.70(0.23,2.14)	0.531	0.47(0.10,2.25)	0.346
CT/CC	0.93(0.59–1.46)	0.742	0.73(0.40–1.32)	0.295
Additive model	0.91(0.62,1.34)	0.641	0.73(0.44,1.23)	0.236
MMP2				
rs7201				
AA	Reference		Reference	
CA	1.08(0.67,1.74)	0.757	0.79(0.42,1.50)	0.471
CC	1.18(0.48,2.90)	0.713	1.10(0.30,4.05)	0.890
CA/CC	1.10(0.70,1.73)	0.683	0.86(0.47,1.55)	0.611
Additive model	1.09(0.77–1.55)	0.635	0.93(0.57–1.53)	0.785
rs2285053				
CC	Reference		Reference	
CT	0.81(0.51,1.31)	0.394	1.40(0.74,2.63)	0.304
TT	1.44(0.62,3.32)	0.394	1.15(0.39,3.46)	0.797
CT/TT	0.90(0.58,1.41)	0.650	1.34(0.74,2.43)	0.327
Additive model	1.01(0.72–1.44)	0.917	1.20(0.76–1.90)	0.438
rs243864				
TT	Reference		Reference	
CT	0.84(0.48–1.49)	0.550	1.16(0.55–2.45)	0.699
CC	9.40(0.88–100.44)	0.064	0.89(0.13–6.14)	0.909
CT/CC	0.96(0.56–1.68)	0.897	1.11(0.55–2.26)	0.770
Additive model	1.10(0.66–1.84)	0.705	1.05(0.58–1.92)	0.864

Note: ^aAdjusted for age, sex, smoking, and drinking.

of IS, no statistically significant association was observed; thus, large-sample studies should be confirmed in the Chinese population. Admittedly, there were some limitations of this study, such as, the genes enrolled in this study may be affected by many SNPs, here we selected some of them,

therefore our study was not comprehensive enough; moreover, the study failed to assess the protein expression in patients, which protein plays a decisive role; finally, the sample size of this study was relatively small, which may affect the statistical power.

Table 3 Association Between Genetic Variations and Types of Ischemic Stroke Risk

Genotype	Small-Vessel Occlusion		Large-Artery		Cardioembolism		Other Type	
	OR (95% CI) ^a	P value	OR (95% CI) ^a	P value	OR (95% CI) ^a	P value	OR (95% CI) ^a	P value
rs1800587								
GG	Reference		Reference		Reference		Reference	
GA	0.59(0.29–1.21)	0.151	0.93(0.50–1.74)	0.828	0.89(0.31–2.57)	0.822	0.76(0.40–1.44)	0.399
AA	–	–	0.65(0.09–4.50)	0.658	–	–	0.63(0.09–4.26)	0.632
GA/AA	0.63(0.31–1.28)	0.202	0.91(0.50–1.66)	0.751	0.97(0.34–2.78)	0.958	0.75(0.41–1.38)	0.354
Additive model	0.70(0.36–1.37)	0.299	0.89(0.53–1.54)	0.694	1.06(0.40–2.82)	0.906	0.77(0.45–1.33)	0.346
rs689466								
TT	Reference		Reference		Reference		Reference	
CT	2.51(1.22–5.16)	0.012	0.86(0.54–1.38)	0.535	1.45(0.58–3.63)	0.432	1.49(0.88–2.53)	0.138
CC	3.27(0.40–26.84)	0.270	1.83(0.37–9.08)	0.461	0.91(0.15–5.39)	0.914	2.33(0.49–11.16)	0.290
CT/CC	2.53(1.26–5.07)	0.009	0.91(0.57–1.45)	0.686	1.35(0.57–3.23)	0.499	1.56(0.93–2.61)	0.094
Additive model	2.26(1.19–4.28)	0.013	0.99(0.65–1.49)	0.941	1.18(0.58–2.45)	0.641	1.51(0.96–2.40)	0.078
rs3918242								
CC	Reference		Reference		Reference		Reference	
CT	1.25(0.49–3.19)	0.641	0.87(0.46–1.61)	0.648	0.31(0.11–0.91)	0.033	0.62(0.33–1.17)	0.137
TT	0.27(0.05–1.58)	0.146	2.23(0.29–25.14)	0.517	–	–	–	–
CT/TT	1.01(0.44–2.32)	0.987	0.92(0.50–1.69)	0.790	0.39(0.14–1.09)	0.072	0.69(0.37–1.29)	0.239
Additive model	0.86(0.43–1.71)	0.661	0.98(0.57–1.71)	0.954	0.55(0.23–1.35)	0.192	0.80(0.45–0.42)	0.435
rs5275								
AA	Reference		Reference		Reference		Reference	
GA	0.49(0.22–1.07)	0.072	1.28(0.76–2.15)	0.350	1.47(0.55–3.97)	0.443	1.18(0.67–2.07)	0.574
GG	0.31(0.12–0.80)	0.016	0.97(0.50–1.88)	0.927	0.83(0.24–2.95)	0.775	0.54(0.27–1.10)	0.089
GA/GG	0.45(0.21–0.95)	0.036	1.20(0.74–1.93)	0.462	1.20(0.49–2.96)	0.686	0.96(0.57,1.61)	0.874
Additive model	0.60(0.39–0.92)	0.020	1.05(0.75–1.46)	0.782	0.94(0.50–1.78)	0.855	0.81(0.57,1.14)	0.217

Note: ^aAdjusted for age, sex, smoking, and drinking; the results with a significant difference are in bold.

In summary, our study suggested that *PTGS2* rs689466 C and rs5275 A were potentially associated with IS subtype of small-vessel occlusion risk. Our result should be confirmed with further large sample sized studies.

Ethical Statement and Consent

The study complied with the Declaration of Helsinki and was approved by the Institutional Review Board of the Nanjing First Hospital, and all participants were written informed consent.

Author Contributions

All authors contributed to data analysis, drafting or revising the article, have agreed on the journal to which the article will be submitted, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Funding

This study was supported by the Innovation Team of Jiangsu Provincial Health-Strengthening Engineering by

Science and Education (CXTDB2017008) and Jiangsu Youth Medical Talents Training Project to BH (QNRC2016066).

Disclosure

The authors report no conflicts of interest in this work.

References

1. Diseases GBD, Injuries C. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2020;396(10258):1204–1222.
2. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. *Stroke*. 1993;24(1):35–41. doi:10.1161/01.STR.24.1.35
3. Zhang LF, Yang J, Hong Z, et al. Proportion of different subtypes of stroke in China. *Stroke*. 2003;34(9):2091–2096. doi:10.1161/01.STR.0000087149.42294.8C
4. Bevan S, Traylor M, Adib-Samii P, et al. Genetic heritability of ischemic stroke and the contribution of previously reported candidate gene and genome-wide associations. *Stroke*. 2012;43(12):3161–3167. doi:10.1161/STROKEAHA.112.665760

5. Kelly PJ, Lemmens R, Tsvigoulis G. Inflammation and stroke risk: a new target for prevention. *Stroke*. 2021;52(8):2697-2706. doi:10.1161/STROKEAHA.121.034388.
6. Della Corte V, Tuttolomondo A, Pecoraro R, Di Raimondo D, Vassallo V, Pinto A. Inflammation, endothelial dysfunction and arterial stiffness as therapeutic targets in cardiovascular medicine. *Curr Pharm Des*. 2016;22(30):4658-4668. doi:10.2174/1381612822666160510124801
7. Pei J, You X, Fu Q. Inflammation in the pathogenesis of ischemic stroke. *Front Biosci*. 2015;20(4):772-783. doi:10.2741/4336
8. Shekhar S, Cunningham MW, Pabbidi MR, Wang S, Booz GW, Fan F. Targeting vascular inflammation in ischemic stroke: recent developments on novel immunomodulatory approaches. *Eur J Pharmacol*. 2018;833:531-544. doi:10.1016/j.ejphar.2018.06.028
9. Zare Rafie M, Esmailzadeh A, Ghoreishi A, Tahmasebi S, Faghihzadeh E, Elahi R. IL-38 as an early predictor of the ischemic stroke prognosis. *Cytokine*. 2021;146:155626. doi:10.1016/j.cyto.2021.155626
10. Lehmann A, Alfieri DF, de Araujo MCM, et al. Immune-inflammatory, coagulation, adhesion, and imaging biomarkers combined in machine learning models improve the prediction of death 1 year after ischemic stroke. *Clin Exp Med*. 2021;1-3. doi:10.1007/s10238-021-00732-w.
11. Palm F, Aigner A, Pussinen PJ, et al. Association of a multigenetic pro-inflammatory profile with ischaemic stroke. *Cerebrovasc Dis*. 2020;49(2):170-176. doi:10.1159/000507042
12. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. *Nat Rev Drug Discov*. 2012;11(8):633-652.
13. Goracy I, Kaczmarczyk M, Ciechanowicz A, et al. Polymorphism of interleukin 1B may modulate the risk of ischemic stroke in polish patients. *Medicine*. 2019;55(9):558.
14. Tuttolomondo A, Pecoraro R, Casuccio A, et al. Peripheral frequency of CD4+ CD28- cells in acute ischemic stroke: relationship with stroke subtype and severity markers. *Medicine*. 2015;94(20):e813. doi:10.1097/MD.0000000000000813
15. Li WX, Dai SX, Wang Q, et al. Integrated analysis of ischemic stroke datasets revealed sex and age difference in anti-stroke targets. *PeerJ*. 2016;4:e2470. doi:10.7717/peerj.2470
16. Hellmann J, Tang Y, Zhang MJ, et al. Atf3 negatively regulates Ptg2/ Cox2 expression during acute inflammation. *Prostaglandins Other Lipid Mediat*. 2015;116-117:49-56. doi:10.1016/j.prostaglandins.2015.01.001
17. Su Z, Wu F. Inflammatory factors induce thrombosis through the miR-146b-3p/p38MAPK/COX-2 pathway. *Biomed Res Int*. 2020;2020:8718321. doi:10.1155/2020/8718321
18. Wu G, Cai H, Cai H, et al. Influence of the cyclooxygenase-2 gene -765G/C and -1195G/A polymorphisms on development of ischemic stroke. *J Stroke Cerebrovasc Dis*. 2016;25(9):2126-2135. doi:10.1016/j.jstrokecerebrovasdis.2016.06.001
19. Oliveira-Filho J, Ornellas ACP, Zhang CR, et al. COX-2 rs20417 polymorphism is associated with stroke and white matter disease. *J Stroke Cerebrovasc Dis*. 2015;24(8):1817-1822. doi:10.1016/j.jstrokecerebrovasdis.2015.04.018
20. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. *Circ Res*. 2002;90(3):251-262. doi:10.1161/res.90.3.251
21. Anthony DC, Ferguson B, Matyzak MK, Miller KM, Esiri MM, Perry VH. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. *Neuropathol Appl Neurobiol*. 1997;23(5):406-415. doi:10.1111/j.1365-2990.1997.tb01315.x
22. Clark AW, Krekoski CA, Bou SS, Chapman KR, Edwards DR. Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. *Neurosci Lett*. 1997;238(1-2):53-56. doi:10.1016/S0304-3940(97)00859-8
23. Lo EH, Wang X, Cuzner ML. Extracellular proteolysis in brain injury and inflammation: role for plasminogen activators and matrix metalloproteinases. *J Neurosci Res*. 2002;69(1):1-9. doi:10.1002/jnr.10270
24. Chang JJ, Stanfill A, Pourmotabbed T. The role of matrix metalloproteinase polymorphisms in ischemic stroke. *Int J Mol Sci*. 2016;17(8):1323. doi:10.3390/ijms17081323
25. Wang L, Deng L, Yuan R, Liu J, Li Y, Liu M. Association of matrix metalloproteinase 9 and cellular fibronectin and outcome in acute ischemic stroke: a systematic review and meta-analysis. *Front Neurol*. 2020;11:523506. doi:10.3389/fneur.2020.523506
26. Rempe RG, Hartz AMS, Bauer B. Matrix metalloproteinases in the brain and blood-brain barrier: versatile breakers and makers. *J Cereb Blood Flow Metab*. 2016;36(9):1481-1507. doi:10.1177/0271678X16655551
27. Zhong C, Yang J, Xu T, et al. Serum matrix metalloproteinase-9 levels and prognosis of acute ischemic stroke. *Neurology*. 2017;89(8):805-812. doi:10.1212/WNL.0000000000004257
28. Niu F, Wei B, Yan M, Li J, Ouyang Y, Jin T. Matrix metalloproteinase-2 gene polymorphisms are associated with ischemic stroke in a Hainan population. *Medicine*. 2018;97(39):e12302. doi:10.1097/MD.00000000000012302
29. Guo D, Zhu Z, Zhong C, et al. Prognostic metrics associated with inflammation and atherosclerosis signaling evaluate the burden of adverse clinical outcomes in ischemic stroke patients. *Clin Chem*. 2020;66(11):1434-1443. doi:10.1093/clinchem/hvaa201
30. Pan Y, He B, Sun H, et al. Susceptibility of PON1/PON2 genetic variations to ischemic stroke risk in a Chinese Han population. *Pharmacogenomics Pers Med*. 2020;13:563-570.
31. Vargas-Alarcon G, Perez-Mendez O, Gonzalez-Pacheco H, et al. The rs508487, rs236911, and rs236918 genetic variants of the proprotein convertase subtilisin-kexin type 7 (PCSK7) gene are associated with acute coronary syndrome and with plasma concentrations of HDL-cholesterol and triglycerides. *Cells*. 2021;10(6):1444. doi:10.3390/cells10061444
32. Revilla M, Obach V, Cervera A, Davalos A, Castillo J, Chamorro A. A -174G/C polymorphism of the interleukin-6 gene in patients with lacunar infarction. *Neurosci Lett*. 2002;324(1):29-32. doi:10.1016/S0304-3940(02)00169-6
33. Lindsberg PJ, Grau AJ. Inflammation and infections as risk factors for ischemic stroke. *Stroke*. 2003;34(10):2518-2532. doi:10.1161/01.STR.0000089015.51603.CC
34. Tuttolomondo A, Maida C, Pinto A. Diabetic foot syndrome as a possible cardiovascular marker in diabetic patients. *J Diabetes Res*. 2015;2015:268390. doi:10.1155/2015/268390
35. Tuttolomondo A, Di Raimondo D, Pecoraro R, et al. HLA and killer cell immunoglobulin-like receptor (KIRs) genotyping in patients with acute ischemic stroke. *J Neuroinflammation*. 2019;16(1):88. doi:10.1186/s12974-019-1469-5
36. Herschman HR. Function and regulation of prostaglandin synthase 2. *Adv Exp Med Biol*. 1999;469:3-8.
37. Chen GZ, Shan XY, Cheng GP, Tao HM. Cyclooxygenase-2 genetic polymorphism and stroke subtypes in Chinese. *J Mol Neurosci*. 2013;51(2):467-473. doi:10.1007/s12031-013-0078-5
38. Li J, Lu X, Zou X, et al. COX-2 rs5275 and rs689466 polymorphism and risk of lung cancer: a PRISMA-compliant meta-analysis. *Medicine*. 2018;97(35):e11859. doi:10.1097/MD.00000000000011859
39. Lurie G, Terry KL, Wilkens LR, et al. Pooled analysis of the association of PTGS2 rs5275 polymorphism and NSAID use with invasive ovarian carcinoma risk. *Cancer Causes Control*. 2010;21(10):1731-1741. doi:10.1007/s10552-010-9602-x
40. Shan XY, Chen GZ, Cheng GP, Tao HM. Cyclooxygenase 2 genetic polymorphism may increase the risk of developing leukoaraiosis in Chinese. *J Mol Neurosci*. 2013;51(2):461-466. doi:10.1007/s12031-013-0066-9

41. Zhao L, Fang J, Zhou M, et al. Interaction between COX-1 and COX-2 increases susceptibility to ischemic stroke in a Chinese population. *BMC Neurol*. 2019;19(1):291. doi:10.1186/s12883-019-1505-1
42. Maguire J, Thakkinian A, Levi C, et al. Impact of COX-2 rs5275 and rs20417 and GPIIb rs5918 polymorphisms on 90-day ischemic stroke functional outcome: a novel finding. *J Stroke Cerebrovasc Dis*. 2011;20(2):134–144. doi:10.1016/j.jstrokecerebrovasdis.2009.10.011
43. Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. *Stroke*. 1998;29(5):1020–1030. doi:10.1161/01.STR.29.5.1020
44. Zhang B, Ye S, Herrmann SM, et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. *Circulation*. 1999;99(14):1788–1794. doi:10.1161/01.CIR.99.14.1788
45. Ye S. Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. *Matrix Biol*. 2000;19(7):623–629. doi:10.1016/S0945-053X(00)00102-5
46. Zhang B, Henney A, Eriksson P, Hamsten A, Watkins H, Ye S. Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1. *Hum Genet*. 1999;105(5):418–423. doi:10.1007/s004390051124.
47. Montaner J, Fernandez-Cadenas I, Molina CA, et al. Safety profile of tissue plasminogen activator treatment among stroke patients carrying a common polymorphism (C-1562T) in the promoter region of the matrix metalloproteinase-9 gene. *Stroke*. 2003;34(12):2851–2855. doi:10.1161/01.STR.0000098648.54429.1C
48. Zhao JH, Xu YM, Xing HX, et al. Associations between matrix metalloproteinase gene polymorphisms and the development of cerebral infarction. *Gene Mol Res*. 2016;14(4):19418–19424. doi:10.4238/2015.December.30.3
49. He T, Wang J, Wang XL, Deng WS, Sun P. Association between the matrix metalloproteinase-9 rs3918242 polymorphism and ischemic stroke susceptibility: a meta-analysis. *J Stroke Cerebrovasc Dis*. 2017;26(5):1136–1143. doi:10.1016/j.jstrokecerebrovasdis.2016.12.036

Pharmacogenomics and Personalized Medicine

Dovepress

Publish your work in this journal

Pharmacogenomics and Personalized Medicine is an international, peer-reviewed, open access journal characterizing the influence of genotype on pharmacology leading to the development of personalized treatment programs and individualized drug selection for improved safety, efficacy and sustainability. This journal is indexed

on the American Chemical Society's Chemical Abstracts Service (CAS). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/pharmacogenomics-and-personalized-medicine-journal>